Volume 33 1973

Psycho—pharmacologia

Managing Editors

J. O. Cole M. Hamilton E. Jacobsen C. Kornetsky R. W. Russell

Editorial Board

D. Bovet, Sassari J. O. Cole, Boston J. Delay, Paris J. Elkes, Baltimore
M. Hamilton, Leeds H. Isbell, Lexington E. Jacobsen, København
M. E. Jarvik, Los Angeles S. S. Kety, Boston C. Kornetsky, Boston
R. W. Russell, Bedford Park M. Shepherd, London Hannah Steinberg, London
E. Strömgren, Risskov A. Wikler, Lexington

Advisory Board

M. Adler, Philadelphia N.-E. Andén, Göteborg J. Angst, Zürich J. B. Appel, Columbia, SC
S. Barondes, La Jolla A. M. Barrett, Leeds H. Barry III, Pittsburgh H. Blaschko, Oxford
D. Booth, Birmingham H. Brill, New York
P. Carlton, New Brunswick C. K. Connors, Boston P. B. Dews, Boston
A. DiMascio, Boston E. Domino, Ann Arbor J. C. Eccles, Buffalo
U. S. von Euler, Stockholm A. Fessard, Paris M. Fink, New York
S. Fisher, Boston R. Fog, Roskilde S. Garattini, Milano S. Gershon, New York
S. C. Goldberg, Chevy Chase S. P. Grossman, Chicago L.-M. Gunne, Uppsala
H. Hanson, West Point J. Harvey, Iowa City H. E. Hill, Lexington
R. Hinde, Cambridge H. Hippius, München L. E. Hollister, Palo Alto
O. Hornykiewicz, Toronto E. Hosoya, Tokyo R. P. Hullin, Leeds S. Irwin, Portland
J. Jaffe, Washington W. Janke, Düsseldorf R. Jewett, Atlanta
R. T. Jones, San Francisco M. Jouvet, Lyon C. R. B. Joyce, Basel D. Joyce, London
M. Katz, Rockville, MD R. Kelleher, Boston K. F. Killam, Davis
G. Klerman, Boston N. S. Kline, Orangeburg M. H. Lader, London I. P. Lapin, Leningrad
L. Lasagna, Rochester V. G. Laties, Rochester A. Latz, Raanana, Israel
O. Lingjærde, Tromsø R. Lipman, Rockville A. Lubin, San Diego E. Marley, London
W. R. Martin, Lexington J. L. McGaugh, Irvine D. E. McMillan, Chapel Hill
N. Mello, Washington A. F. Mirsky, Boston C. Niemegeers, Beerse
S. Norton, Kansas City D. Overton, Philadelphia G. Pampiglione, London P. Pichot, Paris
R. W. Pickens, Minneapolis A. Randrup, Roskilde D. Richter, Epsom K. Rickels, Philadelphia
R. Rodnight, London J. M. Rose, Leeds R. T. Rubin, Los Angeles J. Scheel-Krüger, Roskilde
J. Schildkraut, Boston C. Schuster, Chicago C. Shagass, Philadelphia
P. Silverman, Macclesfield, Ches. F. Sjöqvist, Stockholm J. R. Smythies, Edinburgh
F. Sulser, Nashville R. Taber, Bloomfield T. Thompson, Minneapolis S. Udenfriend, Nutley, NJ
H. Weil-Malherbe, Washington A. Weissman, Groton, CT T. Yanagita, Kawasaki
E. Zaimis, London O. Zangwill, Cambridge

Springer-Verlag
Berlin Heidelberg New York

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publishers.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Springer-Verlag Berlin Heidelberg New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, Wiesbaden

© by Springer-Verlag Berlin Heidelberg 1973

Contents

Subject Index VII

Albuquerque, L. H. de., see Vieira, F. J. A., *et al.* 339
Appel, J. B., see Cameron, O. G. 117
Arévalo, L., see Izquierdo, J. A., *et al.* 103

Babbini, M., Gaiardi, M., Bartoletti, M.: Effects of Morphine on a Quickly Learned Conditioned Suppression in Rats. 329
Bättig, K., see Dittrich, A., *et al.* 369
Baratti, C. M., see Izquierdo, J. A., *et al.* 103
Bartoletti, M., see Babbini, M., *et al.* 329
Bennett, E. L., Rosenzweig, M. R., Wu, S.-Y. C.: Excitant and Depressant Drugs Modulate Effects of Environment on Brain Weight and Cholinesterases 309
Bentkover, S. H., see Gitlow, S. E., *et al.* 135
Bläsig, J., Herz, A., Reinhold, K., Zieglgänsberger, S.: Development of Physical Dependence on Morphine in Respect to Time and Dosage and Quantification of the Precipitated Withdrawal Syndrome in Rats. 19
Blozovski, D., Blozovski, M.: Effets de l'atropine sur l'exploration, l'apprentissage et l'activité électrocorticale chez le Rat au cours du développement . 39
Blozovski, M., see Blozovski, D. 39
Bobon, D. P., see Bobon, J., *et al.* 377
Bobon, J., Bourdouxhe, S., Breulet, M., Parent, M., Bobon, D. P.: Pilot Clinical Trial of Parenteral Lorazepam (Temesta®) in Anxiety States . . 377
Boggan, W. O., Freedman, D. X.: p-Chlorophenylalanine-Induced Alterations in the Behavioral Effects of 5-Hydroxytryptophan. 293
Boulu, R., see Dupeyron, J. P., *et al.* 87
Bourdouxhe, S., see Bobon, J., *et al.* 377
Breulet, M., see Bobon, J., *et al.* 377

Carlini, E. A., see Karniol, I. G. 53
Cavalcante, A. A. R., see Vieira, F. J. A., *et al.* 339
Cameron, O. G., Appel, J. B.: A Behavioral and Pharmacological Analysis of Some Discriminable Properties of *d*-LSD in Rats 117
Casimiro, A. R. S. de, see Vieira, F. J. A., *et al.* 339
Cousens, K., DiMascio, A.: (−)Δ^9-THC as an Hypnotic: An Experimental Study of Three Dose Levels. 355
Cravens, J., see Hartmann, E. 153, 169, 185, 203, 219, 233

Dandiya, P. C., see Kulkarni, S. K. 333
Darley, C. F., see Roth, W. T., *et al.* 259
Dick, P., see Eisenring, J.-J., *et al.* 95
DiMascio, A., see Cousens, K. 355
Dittrich, A., Bättig, K., Zeppelin, I. von: Effects of (−)Δ^9-trans-Tetrahydrocannabinol (Δ^9-THC) on Memory, Attention and Subjective State: A Double Blind Study 369
Dols, L. C. W., see Praag, H. M. van, *et al.* 141
Dupeyron, J. P., Boulu, R., Rossignol, P.: Mise en évidence et mesure d'une activité antiréserpine au niveau central au moyen du réflexe de clignement à la lumière. 87
Dziedzic, S. W., see Gitlow, S. E., *et al.* 135

Eisenring, J.-J., Dick, P., Tissot, R., Yanniotis, G.: Association L-Dopa, désipramine et inhibiteur de la décarboxylase dans le traitement de la dépression 95
Escobar, J. I., Flemenbaum, A., Schiele, B. C.: Chlorimipramine: A Double-Blind Comparison of Intravenous Versus Oral Administration in Depressed Patients 111

Figler, M. H.: The Effects of Chlordiazepoxide (Librium) on the Intensity and Habituation of Agonistic Behavior in Male Siamese Fighting Fish 277
Filczewski, M., see Mazurkiewicz-Kwilecki, I. M. 71
Flemenbaum, A., see Escobar, J. I., *et al.* 111
Flentge, F., see Praag, H. M. van, *et al.* 141
Freedman, D. X., see Boggan, W. O. 293

Gaiardi, M., see Babbini, M., *et al.* 329
Ghezzi, D., see Samanin, R., *et al.* 365
Gitlow, S. E., Bentkover, S. H., Dziedzic, S. W., Khazan, N.: Persistence of Abnormal REM Sleep Response to Ethanol as a Result of Previous Ethanol Ingestion 135
Gomes, A. M. L., see Vieira, F. J. A., *et al.* 339
Gondim, F. A. L., see Vieira, F. J. A., *et al.* 339

Hartmann, E., Cravens, J.: The Effects of Long Term Administration of Psychotropic Drugs on Human Sleep: I. Methodology and the Effects of Placebo 153
Hartmann, E., Cravens, J.: The Effects of Long Term Administration of Psychotropic Drugs on Human Sleep: II. The Effects of Reserpine . . . 169
Hartmann, E., Cravens, J.: The Effects of Long Term Administration of Psychotropic Drugs on Human Sleep: III. The Effects of Amitriptyline . 185
Hartmann, E., Cravens, J.: The Effects of Long Term Administration of Psychotropic Drugs on Human Sleep: IV. The Effects of Chlorpromazine 203
Hartmann, E., Cravens, J.: The Effects of Long Term Administration of Psychotropic Drugs on Human Sleep: V. The Effects of Chloral Hydrate . 219
Hartmann, E., Cravens, J.: The Effects of Long Term Administration of Psychotropic Drugs on Human Sleep: VI. The Effects of Chlordiazepoxide 233
Herz, A., see Bläsig, J., *et al.* 19
Hoffmeister, F., Wuttke, W.: Negative Reinforcing Properties of Morphine-Antagonists in Naive Rhesus Monkeys 247
Hollister, L. E., see Roth, W. T., *et al.* 259

Izquierdo, J. A., Baratti, C. M., Torrelio, M., Arévalo, L.: Effects of Food Deprivation, Discrimination Experience and Physostigmine on Choline Acetylase and Acetylcholine Esterase in the Dorsal Hippocampus and Frontal Cortex of Rats 103

Karniol, I. G., Carlini, E. A.: Pharmacological Interaction between Cannabidiol and Δ^9-Tetrahydrocannabinol 53
Khazan, N., see Gitlow, S. E., *et al.* 135
Kleinrok, Z., see Żebrowska-Łupina, I. 267
Kopell, B. S., see Roth, W. T., *et al.* 259
Korf, J., see Praag, H. M. van, *et al.* 141
Kulkarni, S. K., Dandiya, P. C.: Effects of Antidepressant Agents on Open Field Behaviour in Rats 333

Lewander, T., Sjöström, R.: Increase in the Plasma Concentration of Free Tryptophan Caused by Probenecid in Humans 81
Lyon, M., see Nielsen, E. B. 299

Malhotra, M. K.: Cannabiserlebnisse Wuppertaler Schüler 349
Mauron, C., see Samanin, R., *et al.* 365
Mazurkiewicz-Kwilecki, I. M., Filczewski, M.: The Effects of Chronic Treatment with Δ^9-Tetrahydrocannabinol on Catecholamine Synthesis in the Rat 71

Modigh, K.: Effects of Isolation and Fighting in Mice on the Rate of Synthesis of Noradrenaline, Dopamine and 5-Hydroxytryptamine in the Brain . . . 1

Nielsen, E. B., Lyon, M.: Drinking Behaviour and Brain Dopamine: Antagonistic Effect of Two Neuroleptic Drugs (Pimozide and Spiramide) upon Amphetamine- or Apomorphine-Induced Hypodipsia 299

Oliveira, L. M., see Vieira, F. J. A., *et al.* 339

Parent, M., see Bobon, J., *et al.* 377

Praag, H. M. van, Flentge, F., Korf, J., Dols, L. C. W., Schut, T.: The Influence of Probenecid on the Metabolism of Serotonin, Dopamine and their Precursors in Man 141

Reinhold, K., see Bläsig, J., *et al.* 19
Rola, F. H., see Vieira, F. J. A., *et al.* 339
Rosenzweig, M. R., see Bennett, E. L., *et al.* 309
Rossignol, P., see Dupeyron, J. P., *et al.* 87
Roth, W. T., Tinklenberg, J. R., Whitaker, C. A., Darley, C. F., Kopell, B. S., Hollister, L. E.: The Effect of Marihuana on Tracking Task Performance . 259

Samanin, R., Ghezzi, D., Mauron, C., Valzelli, L.: Effect of Midbrain Raphe Lesion on the Antinociceptive Action of Morphine and Other Analgesics in Rats 365
Schiele, B. C., see Escobar, J. I., *et al.* 111
Schut, T., see Praag, H. M. van, *et al.* 141
Sjöström, R., see Lewander, T. 81

Tinklenberg, J. R., see Roth, W. T., *et al.* 259
Tissot, R., see Eisenring, J.-J., *et al.* 95
Torrelio, M., see Izquierdo, J. A., *et al.* 103

Valzelli, L., see Samanin, R., *et al.* 365
Vieira, F. J. A., Weyne, M. E., Oliveira, L. M., Gondim, F. A. L., Casimiro, A. R. S. de, Cavalcante, A. A. R., Gomes, A. M. L., Albuquerque, L. H. de, Rola, F. H.: Induction (Transfer) of an Operant Behaviour by Injection of Brain Extract 339

Weyne, M. E., see Vieira, F. J. A., *et al.* 339
Whitaker, C. A., see Roth, W. T., *et al.* 259
Wu, S.-Y. C., see Bennett, E. L., *et al.* 309
Wuttke, W., see Hoffmeister, F. 247

Yanniotis, G., see Eisenring, J.-J., *et al.* 95

Żebrowska-Łupina, I., Kleinrok, Z.: Behavioural Effects of Yohimbine Administered Intraventricularly in the Rat 267
Zeppelin, I. von, see Dittrich, A., *et al.* 369
Zieglgänsberger, S., see Bläsig, J., *et al.* 19

Indexed in Current Contents

Subject Index

A

Acetylcholinesterase 309
Acquisition 39
Adrenaline 71
Aggression 1, 277
Amitriptyline 185
Amphetamine 299
—, *d* 309
Analgesia 365
Antidepressants 111, 185, 333
—, screening 87
Antireserpine activity 87
Anxiety 377
Apomorphine 299
Atropine 39
Attention 369

B

Behavior 39, 293
—, induction 339
—, stereotyped 333
Brain extract 339
—, injury 309
—, weight 309

C

Cannabidiol 53
Cannabis 349
Catecholamine synthesis 71
Cerebrospinal fluid 81
Chloral hydrate 219
Chlordiazepoxide 233, 277
Chlorimipramine 111
p-Chlorophenylalanine 293
Chlorpromazine 203
Choline acetylase 103
Cholinesterase 103
Cocaine 247
Codeine 247, 365
Cyclazocine 247

D

Decarboxylase inhibitor 95
Depersonalization 369
Depression 95, 111
Desipramine 95
Discrimination 117
"Dissociation" 117
Dopamine 1, 71, 95, 141, 299
Dorsal hippocampus 103
Drinking behavior 299
Driving, simulated 259
Drugs 153
D-sleep 169, 185

E

EEG 39
Enriched environment 309
Ethanol 135
Exploration 39

F

Fighting 1, 277
Fish 277
Food deprivation 103
Frontal cortex 103

H

Habituation 277
Hallucinogenic drugs 117
5-HT metabolism 141
Human subjects 81, 95, 111, 141, 153, 185, 203, 219, 233, 259, 349, 355, 377
5-Hydroxyindole-acetic acid 81
5-Hydroxytryptamine 1
5-Hydroxytryptophan serotonin 293
Hypodipsia 299

I

Imipramine 111
Insomnia 355
Intraventricular administration 267
Isolation 1

L

L-Dopa 95
Learning 39, 117
—, facilitation 103
Light blink reflex 87
Locomotor activity 267
Lorazepam 377
LSD 117

M

MAOIs 333
Marihuana 259
Maze 39
Memory 369
Meperidine 365
Methadone 365
Methamphetamine 309

Mice 1, 53
Midbrain Raphe lesion 365
Morphine 329, 365
—, dependence 19
—, withdrawal 19
Motor activity 329

N
Nalorphine 247
Naloxone 247
Narcosis 267
Negative reinforcing properties 247
Neuroleptics 299
Noradrenaline 1, 71

O
Ontogeny 39

P
Pentazocine 247
Pharmalogical interaction 53
Phenobarbital 309
Physostigmine 103
Pimozide 299
Placebo 153
Plasma, human 81
Probenecid 81, 141
Propiramfumarate 247
Propoxyphene 365
Psychotropic drugs 153, 169, 203, 219, 233

R
Rabbits 53, 87
Rats 19, 39, 53, 71, 103, 117, 135, 267, 293, 299, 309, 329, 333, 339, 365
REM sleep 135
Reserpine 169
Retention 39
Rhesus monkeys 247

S
School children 349
Self-administration 247
Serotonin 141, 365
Skinner box 339
Sleep 153, 169, 185, 203, 219, 233, 355
Spiramide 299
State-dependent learning 177
Suppression, conditioned 329

T
Temestra® 377
Temperature 267
Temporal disintegration 369
Δ^9THC 53, 71, 355, 369
Tracking 259
Tricyclic compounds MAOIs 333
Tryptophan 81, 141
—, hydroxylase activity 1
Tyrosine-hydroxylase activity 1
—, metabolism 141

Y
Yohimbine 267

Instructions to Authors

1. Papers will be published in **English, French or German.**

2. Authors should submit **manuscripts together with two copies.** The original illustration material (original drawings etc.) and two copies should be submitted together with the manuscript.

3. The text should be as **clear and concise** as possible. Both form and content of the paper should be carefully checked to exclude the need for corrections in proof. A charge will be made for changes introduced after the manuscript has been set in type.

4. **Manuscripts** should be typewritten, double-spaced, on one side of letter size paper and with wider margin on the left. The author should mark in the margin where figures and tables may be inserted. All pages should be numbered consecutively. Tables, footnotes and legends for illustrations should be typed (double-spaced) on separate pages. Use the metric system for text and figures.

5. The **first page** should bear:
the title; the name(s) of the author(s); the name of the laboratory where the work was carried out; a running title of not more than 67 typewriter strokes; footnotes to the title (marked by asterisks).

6. Each paper should be preceded by a brief **abstract** in English concerned with the methods used and with the experimental results which should be presented in such a way that it is possible for the reader to assess their significance. It should be as short as possible and should **not exceed 200 words.**
French and German articles should also have an **English translation of the title.**

7. Immediately following the abstract, some relevant **key words** should be supplied for subject indexing.

8. Articles dealing with **original investigations** should first state the problem concisely and arrange the material under Methods, Results, Discussion, References.

9. **Footnotes** should be kept to a minimum and numbered consecutively throughout the paper. Footnotes referring to the heading of the article are to be marked by asterisks.

10. The **bibliography** should include only work cited in the text. References should be listed alphabetically at the end of the paper as follows: *journal papers*—names and initials of all authors, full title, journal abbreviated in accordance with World Medical Periodicals, volume number, first and last page numbers, year in parentheses; *books*—names of authors, full title, edition, place, publisher, year. *Examples:*

Latz, A., Bain, G. T., Kornetsky, C.: Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. Psychopharmacologia (Berl.) **14**, 23—32 (1960).

Fisher, S., Cole, J. O., Rickels, K., Uhlenhuth, E. H.: Drug set interaction: The effect of expectation on drug response in outpatients. In: Neuropsychopharmacology. Bradley, P. B., Flugle, F., and Hoch, P., eds., vol. 3, pp. 140—156. Amsterdam: Elsevier 1964.

Several publications by the same author or group of authors should be listed in chronological order; those that appear in the same year should be distinguished by the suffixes a, b, c etc. Citations in the text should be given in parentheses, e.g. (Beckman, 1958; Brown, 1963), except when the author's name is part of a sentence, e.g. "Man (1966) reported that . . ." When a paper with more than two authors is cited, all authors are named the first time, but subsequently only the first authors, e.g. (Miller *et al.*, 1963).

11. Figures should be separated from the text and numbered. They should be restricted to a minimum. Descriptions in captions should not be expanded in the text, nor should the same data be given in both graph and table form. Coloured or previously published illustrations are not usually accepted. Original drawings and graphs should be drawn in Indian ink with lines of uniform thickness. Where possible, **figures should be grouped,** bearing in mind maximum display area is 108×177 mm ($4^1/_4 \times 7''$). In general it should be assumed that the same degree of reduction will apply to all figures in the same paper. Inscriptions should allow for any reduction in scale—a capital letter should be about 1.8 mm high in the final version. If figures have to be redrawn for the blockmaker, this may cause considerable delay in publication. Photographs should be sharp, well-contrasted glossy prints at right angles. Authors should mark them with Letraset (Instant Lettering).

CURRENT CONTENTS® CLINICAL PRACTICE

A NEW SERVICE THAT MAKES CONTINUING MEDICAL EDUCATION EASIER

When it comes to patient care, you know you've got to stay on top of what's new. But with busy schedules giving less time for reading, it's easy to miss key journal articles relevant to your work. *Current Contents/Clinical Practice* is an easy way to keep up with what's being published.



Each week—in an easy-to-scan, pocket-sized format, *CC®/CP* will bring you reproduced *tables of contents* from 700 of the world's most important clinical journals. By spending less than an hour with *CC/CP*—it's ideal for browsing between rounds and work-ups—you'll efficiently organize your reading. No need to handle a single journal until you're ready to read the articles you've preselected by examining titles on contents pages. And you'll be able to see what's in journals you don't normally check. The hard-to-get ones. The foreign ones.

For less than $3 a week you can make *sure* you find out what's new in patient care while it's still new. Subscribe today.

©1972 ISI

Please enter my order for *Current Contents®/Clinical Practice* and invoice me later. 337

- U.S.A., Canada, & Mexico: $135 per year
- All other locations: $165 per year

☐ 2 years – save 5% ☐ 3 years – save 10% ☐ 4 years – save 15% ☐ 5 years – save 20% ☐ 6 years – save 25%

☐ Please send information on discounts available for group subscriptions.

Name_____

Organization_____

Address_____

City_____ State_____

Zip_____ Country_____

GUARANTEE: Your money refunded in full if you are not satisfied with *Current Contents/Clinical Practice* after receiving six of the weekly issues.

ISI® Institute for Scientific Information
325 Chestnut Street, Philadelphia, Pennsylvania 19106 U.S.A., Tel.: (215) 923 3300

The journal you are reading and 5000 others are regularly covered in *CURRENT CONTENTS®*.

Responsible for advertisements: L. Siegel, D-1000 Berlin 15, Kurfürstendamm 237
Telephone: (030) 8821031, Telex: 01-85411
Springer-Verlag, Berlin, Heidelberg, New York
Printed in Germany by Wiesbadener Graphische Betriebe GmbH, D-6200 Wiesbaden

© by Springer-Verlag, Berlin Heidelberg 1973

A 21682 D

Psycho-pharmacologia

Volume 34 Fasc. 1 1974

Animal Studies

1 **Allen, C., Allen, B. S., Rake, A. V.:** Pharmacological Distinctions between "Active" and "Passive" Avoidance Memory Formation as Shown by Manipulation of Biogenic Amine Active Compounds

37 **Gianutsos, G., Hynes, M. D., Puri, S. K., Drawbaugh, R. B., Lal, H.:** Effect of Apomorphine and Nigrostriatal Lesions on Aggression and Striatal Dopamine Turnover during Morphine Withdrawal: Evidence for Dopaminergic Supersensitivity in Protracted Abstinence

45 **Magour, S., Coper, H., Fähndrich, Ch.:** The Effects of Chronic Treatment with *d*-Amphetamine on Food Intake, Body Weight, Locomotor Activity and Subcellular Distribution of the Drug in Rat Brain

63 **Bite, A., György, L.:** Studies on the Potentiation of the Antinociceptive Effect of Oxotremorine by Tetrabenazine in Mice

71 **Broekkamp, C. L. E., van Rossum, J. M.:** Effects of Apomorphine on Self-Stimulation Behavior

81 **Quenzer, L. F., Feldman, R. S., Moore, J. W.:** Toward a Mechanism of the Anti-Aggression Effects of Chlordiazepoxide in Rats

Human Pharmacology

11 **Murphy, D. L., Baker, M., Goodwin, F. K., Miller, H., Kotin, J., Bunney, W. E., Jr.:** L-Tryptophan in Affective Disorders: Indoleamine Changes and Differential Clinical Effects

21 **Gerlach, J., Reisby, N., Randrup, A.:** Dopaminergic Hypersensitivity and Cholinergic Hypofunction in the Pathophysiology of Tardive Dyskinesia

55 **Kopell, B. S., Wittner, W. K., Lunde, D. T., Wolcott, L. L., Tinklenberg, J. R.:** The Effects of Methamphetamine and Secobarbital on the Contingent Negative Variation Amplitude

Indexed in Current Contents

Springer-Verlag
Berlin · Heidelberg · New York

Psychopharmacologia (Berl.) – PSYPAG 34(1) 1–94 (1974) 9. I. 1974